Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 30, 2009 08:30 ET | Source: Cleveland BioLabs, Inc.

Cleveland BioLabs Concludes Private Placement of Series D Preferred Stock and Common Stock Warrants

BUFFALO, NY--(Marketwire - March 30, 2009) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) (the "Company") announced today that it concluded its offering of series D convertible preferred stock ("Series D...
March 25, 2009 08:30 ET | Source: Cleveland BioLabs, Inc.

Cleveland BioLabs to Host Investor Update Conference Call on March 31

BUFFALO, NY--(Marketwire - March 25, 2009) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that it will host a conference call at 10:00 a.m. EDT on March 31, to provide an update on the...
March 23, 2009 08:30 ET | Source: Cleveland BioLabs, Inc.

Cleveland Biolabs Consummates Private Placement of Series D Preferred Stock and Common Stock Warrants

BUFFALO, NY--(Marketwire - March 23, 2009) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) (the "Company") announced today that it has raised approximately $2,900,00 in capital through a private...
February 17, 2009 08:00 ET | Source: Cleveland BioLabs, Inc.

Cleveland BioLabs Consummates Private Placement of Series D Preferred Stock and Common Stock Warrants

BUFFALO, NY--(Marketwire - February 17, 2009) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) (the "Company") announced today that it has raised approximately $1,700,000 in capital through a private...
January 20, 2009 09:00 ET | Source: Cleveland BioLabs, Inc.

Cleveland BioLabs Completes Dosing of Fourth Cohort in Initial Safety Study for Protectan CBLB502

BUFFALO, NY--(Marketwire - January 20, 2009) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that dosing of the fourth cohort of healthy volunteers has been completed in the initial human...
December 29, 2008 08:00 ET | Source: Cleveland BioLabs, Inc.

Cleveland BioLabs Reports Advances in Curaxin Anticancer Program

BUFFALO, NY--(Marketwire - December 29, 2008) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced several advances in the development of Curaxins, the leading class of drug candidates in the...
December 01, 2008 08:18 ET | Source: Cleveland BioLabs, Inc.

Cleveland BioLabs Announces Appointment of International Expert in Chemical, Biological and Radiological/Nuclear Threat Countermeasures as Senior Vice President of Public Health and Government Services

BUFFALO, NY--(Marketwire - December 1, 2008) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced the appointment of Michelle Ross, DVM, M.S, Ph.D., as Senior Vice President of Public Health and...
November 03, 2008 08:30 ET | Source: Cleveland BioLabs, Inc.

Cleveland BioLabs to Present at Rodman and Renshaw 10th Annual Healthcare Conference

BUFFALO, NY--(Marketwire - November 3, 2008) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Company will present at the Rodman and Renshaw 10th Annual Healthcare Conference in New...
October 27, 2008 08:30 ET | Source: Cleveland BioLabs, Inc.

Cleveland BioLabs Protectan CBLB612 Demonstrates Significant Reduction of Myelosuppression in Mouse Model of Chemotherapy

BUFFALO, NY--(Marketwire - October 27, 2008) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced results of a series of studies demonstrating Protectan CBLB612's ability to substantially reduce...
October 24, 2008 17:26 ET | Source: Cleveland BioLabs, Inc.

Cleveland BioLabs Receives Letter From NASDAQ Citing Non-Compliance With Global Market Listing Requirements

BUFFALO, NY--(Marketwire - October 24, 2008) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that on October 22, 2008, the Company received a letter from The NASDAQ Stock Market notifying...